Table 1. Capecitabine-specific skin toxicity – frequency of occurrence.
|
CAPIRI+cetuximab, (n=78)
|
CAPOX+cetuximab, (n=71)
|
Both arms (n=149)
|
||||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | P-value, Fisher's exact test (two-sided) | n | % | ||
| Grade 0a | 58 | 74.4 | 43 | 60.6 | 0.81 | 101 | 67.8 | |
| Grade 1a | 9 | 11.5 | 7 | 9.9 | 0.81 | 16 | 10.7 | |
| Grade 2a | 9 | 11.5 | 13 | 18.3 | 0.26 | 22 | 14.8 | |
| Grade 3a | 2 | 2.6 | 8 | 11.3 | 0.048 | 10 | 6.7 | |
Abbreviations: CAPIRI=combination of capecitabine and irinotecan; CAPOX=combination of capecitabine with oxaliplatin.
a
According to the National Cancer Institute Common Toxicity Criteria of Adverse Events, version 3.0. The bold value indicates statistical significance (P<0.05).